1) 1p loss of heterozygosity
1p杂合性缺失
1.
Objective To set up the clinical examination method for 1p loss of heterozygosity(LOH).
目的建立临床检测少突胶质细胞瘤1p杂合性缺失的手段。
3) loss of heterozygosity
杂合性缺失
1.
Identification of some macrosatillite sites of chromosome 19 in primary gastric carcinoma with loss of heterozygosity;
19号染色体微卫星杂合性缺失与原发性胃癌的临床关系
2.
Analysis of loss of heterozygosity in tk gene of L5178Y mouse lymphoma cells induced by colchicine and vincristine;
秋水仙碱和长春新碱诱导L5178Y小鼠淋巴瘤细胞tk基因杂合性缺失分析
3.
Study of loss of heterozygosity and microsatellite instabilities of fragile histidine triad gene in gastric carcinoma;
胃癌FHIT基因杂合性缺失及微卫星不稳定性的研究
4) LOH
杂合性缺失
1.
Study on 10q23 LOH and Both Mutation and Expression of PTEN Gene of the Oesophageal Squamous Cell Carcinomas in Chinese Population;
中国人食管癌10q23杂合性缺失和PTEN基因突变及表达研究
2.
Methods PCR-denaturing polyacrylamide gel electrophoresis-silver staining method was used to detect LOH of three mic- rusatellite locus located in the WWOX gene site of 31 breast cancer tissues.
目的检测乳腺癌组织中WWOX基因的杂合性缺失(LOH)状况及WWOX蛋白的表达状况,并探讨其与乳腺癌临床病理参数之间的关系。
3.
Objective:To detect the loss of heterozygosity(LOH) of ING1 gene microsatellite and the expression of p33ING1b protein in lung carcinoma and to investigate their association with the carcinogenesis of lung cancer.
目的:检测肺癌中抑癌基因ING1微卫星杂合性缺失(LOH)及其主要蛋白产物p33ING1b的表达情况,以探讨ING1基因改变与肺癌发生发展的关系。
5) LOH
杂合性缺失(LOH)
1.
Studies show that loss of heterozygosity (LOH) on multiple genetic LOH in clear cell renal carcinoma in 10 genetic locus and to find clues for tumor suppressor genes associated with cc-RCC.
本研究检测肾透明细胞癌等位基因杂合性缺失(LOH)情况,为寻找与肾透明细胞癌相关的抑癌基因提供线索。
2.
Objective:To compare the LOH rate of allelomorphic gene on chromosome 9 at the identical district and site between esophageal squamous carcinoma and cervical squamous carcinoma to explore the related anti-oncogene in common.
目的:比较食管和宫颈鳞状细胞癌组织中9号染色体相同区域七个微卫星位点的等位基因杂合性缺失(LOH)率,探寻与两种鳞癌发生、发展共同相关的抑癌基因。
补充资料：[3-(aminosulfonyl)-4-chloro-N-(2.3-dihydro-2-methyl-1H-indol-1-yl)benzamide]
分子式：C16H16ClN3O3S
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条